Drug intelligence / Profile preview

urokinase + vancomycin

Development stage: Preclinical
Modality: Small Molecules
Administration: Intracatheter

Overview

Urokinase + vancomycin is a combination therapy used in certain medical situations. Vancomycin is a glycopeptide antibiotic used to treat severe bacterial infections, particularly those caused by methicillin-resistant Staphylococcus aureus (MRSA). Urokinase is a thrombolytic agent used to dissolve blood clots. The combination has been documented for use in treating intractable MRSA infections, particularly in cases involving central venous access devices. Vancomycin 50 mg/mL combined with urokinase 1250 units/mL has been used clinically, though further stability studies are needed.

Targets

D-Ala-D-Ala (D-Ala-D-Ala terminus)PLG (Plasminogen)

Beyond the preview

Go deeper on urokinase + vancomycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on urokinase + vancomycin.

Explore the full profile